STO: NANEXA

China's NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products
Policy / Regulatory

China’s NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products

China's National Medical Products Administration (NMPA) released the draft Regulations on the Administration of Radiopharmaceuticals and opened a public comment period through October 20. The draft establishes a dedicated regulatory…

Merck Licenses SciBrunch's Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

Merck Licenses SciBrunch’s Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

FDA Approves Eli Lilly's Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

FDA Approves Eli Lilly’s Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Novo Nordisk Licenses Nanexa's PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Nanexa’s PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes